Compare Stocks → He Is Giving Away Bitcoin (From Crypto Swap Profits) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ALBONASDAQ:AVDLNASDAQ:BLUNASDAQ:LABPNASDAQ:NRXP Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALBOAlbireo Pharma$44.15-0.2%$44.17$16.02▼$45.23$913.91M1.03704,539 shs1.24 million shsAVDLAvadel Pharmaceuticals$17.66-2.4%$15.67$9.50▼$18.85$1.60B1.61.22 million shs443,600 shsBLUBELLUS Health$14.74$14.62$6.38▼$14.76$1.87B0.193.08 million shs3.45 million shsLABPLandos Biopharma$22.36+0.9%$13.40$2.50▼$22.49$69.76M0.1422,061 shs9,082 shsNRXPNRx Pharmaceuticals$3.12+2.3%$33.96$2.21▼$12.00$30.83M1.02179,045 shs96,380 shs7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALBOAlbireo Pharma0.00%0.00%0.00%0.00%0.00%AVDLAvadel Pharmaceuticals+4.57%0.00%+5.05%+32.04%+69.70%BLUBELLUS Health0.00%0.00%0.00%0.00%+2.15%LABPLandos Biopharma+0.87%+2.98%+182.89%+386.82%+687.98%NRXPNRx Pharmaceuticals+1.67%-29.07%-94.55%-93.05%-94.77%He Is Giving Away Bitcoin (Ad)And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right hereMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALBOAlbireo PharmaN/AN/AN/AN/AN/AN/AN/AN/AAVDLAvadel Pharmaceuticals3.2343 of 5 stars4.52.00.00.03.41.70.6BLUBELLUS HealthN/AN/AN/AN/AN/AN/AN/AN/ALABPLandos Biopharma0.3328 of 5 stars1.03.00.00.03.10.80.6NRXPNRx PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALBOAlbireo PharmaN/AN/AN/AN/AAVDLAvadel Pharmaceuticals3.00Buy$22.5727.81% UpsideBLUBELLUS HealthN/AN/AN/AN/ALABPLandos Biopharma2.00Hold$20.42-8.68% DownsideNRXPNRx PharmaceuticalsN/AN/AN/AN/ACurrent Analyst RatingsLatest AVDL, LABP, ALBO, NRXP, and BLU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/9/2024AVDLAvadel PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.004/1/2024LABPLandos BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$50.00 ➝ $20.423/5/2024AVDLAvadel PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $22.003/5/2024AVDLAvadel PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$18.00 ➝ $23.003/5/2024AVDLAvadel PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$27.00 ➝ $29.003/5/2024AVDLAvadel PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$21.00 ➝ $25.003/5/2024AVDLAvadel PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $22.002/6/2024AVDLAvadel PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$21.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALBOAlbireo Pharma$40.58M22.52N/AN/A$9.11 per share4.85AVDLAvadel Pharmaceuticals$27.96M57.21N/AN/A$0.98 per share18.02BLUBELLUS Health$15K124,613.93N/AN/A$3.09 per share4.77LABPLandos Biopharma$18M3.88N/AN/A$10.20 per share2.19NRXPNRx PharmaceuticalsN/AN/AN/AN/A($1.38) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALBOAlbireo Pharma-$34.03M-$6.72N/AN/AN/A-228.51%-97.13%-46.89%N/AAVDLAvadel Pharmaceuticals-$160.28M-$2.04N/A21.28N/AN/A-198.06%-84.51%5/2/2024 (Estimated)BLUBELLUS Health-$76.08M-$0.72N/AN/AN/A-578,586.63%-24.27%-23.14%N/ALABPLandos Biopharma-$21.93M-$3.46N/AN/AN/AN/A-54.92%-49.09%5/10/2024 (Estimated)NRXPNRx Pharmaceuticals-$30.15M-$4.00N/A∞N/AN/AN/A-202.53%5/21/2024 (Estimated)Latest AVDL, LABP, ALBO, NRXP, and BLU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/29/2024Q4 2023NRXPNRx PharmaceuticalsN/A-$0.50-$0.50-$0.50N/AN/A3/21/2024Q4 2023LABPLandos Biopharma-$0.91-$0.99-$0.08-$0.99N/AN/A3/4/2024Q4 2023AVDLAvadel Pharmaceuticals-$0.28-$0.32-$0.04-$0.29$17.41 million$19.45 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALBOAlbireo PharmaN/AN/AN/AN/AN/AAVDLAvadel PharmaceuticalsN/AN/AN/AN/AN/ABLUBELLUS HealthN/AN/AN/AN/AN/ALABPLandos BiopharmaN/AN/AN/AN/AN/ANRXPNRx PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALBOAlbireo PharmaN/A6.326.23AVDLAvadel PharmaceuticalsN/A3.643.36BLUBELLUS HealthN/A33.4233.42LABPLandos BiopharmaN/A6.096.09NRXPNRx PharmaceuticalsN/A0.360.36OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALBOAlbireo Pharma94.25%AVDLAvadel Pharmaceuticals69.19%BLUBELLUS Health90.37%LABPLandos Biopharma49.06%NRXPNRx Pharmaceuticals4.27%Insider OwnershipCompanyInsider OwnershipALBOAlbireo Pharma6.90%AVDLAvadel Pharmaceuticals4.00%BLUBELLUS Health24.17%LABPLandos Biopharma1.30%NRXPNRx Pharmaceuticals21.06%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableALBOAlbireo Pharma13020.70 million19.27 millionOptionableAVDLAvadel Pharmaceuticals15490.58 million86.95 millionOptionableBLUBELLUS Health74126.81 million96.16 millionNot OptionableLABPLandos Biopharma193.12 million3.08 millionNot OptionableNRXPNRx Pharmaceuticals29.88 million7.80 millionOptionableAVDL, LABP, ALBO, NRXP, and BLU HeadlinesSourceHeadlineNRx Pharmaceuticals, Inc. (NRXP) Advances While Market Declines: Some Information for Investorszacks.com - April 19 at 7:06 PMWhy Is NRX Pharmaceuticals (NRXP) Stock Down 29% Today?investorplace.com - April 18 at 8:56 AMNRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stockfinance.yahoo.com - April 18 at 8:39 AMNRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirementfinance.yahoo.com - April 18 at 8:39 AMNRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirementprnewswire.com - April 18 at 8:32 AMNRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stockprnewswire.com - April 18 at 8:30 AMNRx Pharmaceuticals: New Data Demonstrates No Impact Of NRX-101 On Gut Or Vaginal Floramarkets.businessinsider.com - April 17 at 10:07 AMNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infectionsfinance.yahoo.com - April 17 at 10:07 AMNRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)prnewswire.com - April 15 at 8:30 AMNRx Pharmaceuticals Advances in Breakthrough Bipolar Depression Treatmentmsn.com - April 14 at 7:15 PMShort Interest in NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Declines By 88.6%marketbeat.com - April 10 at 9:59 PMNRx Pharma Achieves Data-lock In Phase 2b/3 Suicidal Treatment Resistant Bipolar Depression Studymarkets.businessinsider.com - April 8 at 11:23 AMNRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depressionprnewswire.com - April 8 at 8:30 AMNRx Pharmaceuticals (NRXP) Upgraded to Strong Buy: Here's What You Should Knowzacks.com - April 4 at 1:02 PMNew Strong Buy Stocks for April 4thzacks.com - April 4 at 7:51 AMNew Brain Cap Lets People Play Video Games With Their Mindsmsn.com - April 3 at 9:19 PMRep. Raúl Grijalva announces cancer diagnosisca.news.yahoo.com - April 3 at 4:56 AMWoman, 23, diagnosed with cancer after thinking she was bloated with irritable bowel syndromeca.news.yahoo.com - April 3 at 4:56 AMAlberta creating 2 mental health and addictions organizations, including Crown corporationca.news.yahoo.com - April 2 at 6:55 PMThere’s Nothing Wrong With Having Hooded Eyesmsn.com - April 2 at 6:55 PMA dietitian explains how a 'diet break' can make it easier to lose weight and keep it offmsn.com - April 2 at 6:55 PMNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - April 2 at 1:55 PMNRx Pharmaceuticals reports Q4 resultsmsn.com - April 1 at 12:48 PMNRx Pharmaceuticals (Nasdaq:NRXP) Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updateprnewswire.com - April 1 at 8:28 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAlbireo PharmaNASDAQ:ALBOAlbireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.Avadel PharmaceuticalsNASDAQ:AVDLAvadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.BELLUS HealthNASDAQ:BLUBELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada. As of June 28, 2023, BELLUS Health Inc. operates as a subsidiary of GSK plc.Landos BiopharmaNASDAQ:LABPLandos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that completed Phase Ib clinical trial to treat ulcerative colitis (UC), as well as induce anti-inflammatory effects in CD4+ T cells and other cells in the gastrointestinal tract. The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and Alzheimer's disease; and LABP-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and RA. The company has a strategic research collaboration with KU Leuven and University Hospitals Leuven to investigate the effects of NX-13 on epithelial cells with the inflammatory bowel disease. The company was incorporated in 2017 and is headquartered in Blacksburg, Virginia.NRx PharmaceuticalsNASDAQ:NRXPNRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics based on N-methyl-D-aspartate platform for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated investigational breakthrough therapy for suicidal treatment-resistant bipolar depression and chronic pain; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of acute suicidality in depression. The company has a partnership with Alvogen and Lotus to develop and commercialize NRX-101 for the suicidal bipolar depression treatment, as well as an agreement with Nephron Pharmaceuticals, Inc. to develop ketamine. The company was founded in 2015 and is based in Wilmington, Delaware. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.